Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 27, 2025
Context: The filing serves to furnish a press release dated March 27, 2025, announcing the Company's full-year 2024 financial results.
Key Financial Metrics
The filing text references a press release regarding 2024 results but does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the provided document body.
- ProSense Cryoablation Sales (North America): Reported 42% growth for the 2024 period.
- Other Metrics: The filing text does not provide clear values for total revenue, net income, operating cash flow, or balance sheet items.
Material Changes
The primary material change highlighted is the 42% year-over-year growth in ProSense Cryoablation sales within the North American region for the 2024 fiscal year.
Guidance, Outlook, and Risks
The provided text does not contain specific forward-looking guidance, management commentary beyond the headline growth figure, or detailed risk factors. It solely references the existence of the press release as Exhibit 99.1.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for detailed 2024 revenue, net loss, and cash position figures.
- Verify the specific drivers behind the 42% growth in North American ProSense sales.
- Check for updated 2025 financial guidance or operational milestones not included in this summary filing.
- Confirm the Company's cash runway and liquidity status as of the end of 2024.